Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Defence Therapeutics Inc DTCFF


Primary Symbol: C.DTC

Healthcare Biotechnology
Defence Therapeutics Inc. is a Canada-based biotechnology company working on engineering vaccines and antibody drug conjugates (ADC) products using its proprietary platform. The Company is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological-/biosimilar-based pharmaceuticals used in the treatment of cancer and... see more

Recent & Breaking News (CSE:DTC)

Defence Therapeutics (CSE:DTC) issued notice of allowance for its proprietary Accum technology

John Ballem  January 16, 2023

Defence Accum(TM) Accepted Us Patent to Bolster Its Vaccine Platform Technology IP

Newsfile January 16, 2023

mRNA with Defence's Accum(TM) Program Has Been Initiated

Newsfile January 10, 2023

Defence Therapeutics' (CSE:DTC) AccuTOX reduces cancer nodules

Caroline Egan  December 20, 2022

Breakthrough Results: Defence's Novel AccuTOX(TM) Intranasal Reduced 50% of Cancer Nodules on Animals with Lung Tumors

Newsfile December 20, 2022

Defence's mRNA with Accum(TM) for Cancer Vaccines Update

Newsfile December 15, 2022

Defence Therapeutics Appoints Kwin Grauer to Its Board of Directors

Newsfile December 9, 2022

Defence (CSE:DTC) advancing cancer treatment

Caroline Egan  December 6, 2022

Defence Positioned to Begin Its Anti-Cancer AccuTOX(TM) Phase I Trial with Successful Completion of GLP Studies

Newsfile December 6, 2022

Defence Therapeutics (CSE:DTC) completes Good Laboratory Practice studies on the AccuVAC-PT007 vaccine

John Ballem  November 23, 2022

Defence's Successfull Study on the AccuVAC-PT007 Vaccine Targeting Cervical Cancer

Newsfile November 23, 2022

Defence Therapeutics (CSE:DTC) completes $2.3M debenture financing

John Ballem  November 17, 2022

Defence Therapeutics Completes Fully-Subscribed Debenture Financing of $2,355,000

Newsfile November 16, 2022

BTV Features: Defence Therapeutics, Volatus Aerospace, NGEx Minerals, York Harbour Metals, & AuTECO Minerals

Newsfile November 10, 2022

mRNA Program: Defence to Apply Its Propriatry Accum(TM) Technology in The Design of Messenger RNA Anti-Cancer Vaccines

Newsfile October 31, 2022

Defence Therapeutics Announces Debenture Financing

Newsfile October 28, 2022

Defence Therapeutics (CSE:DTC) initiates lung cancer treatment program with its AccuTOX formulation

Jonathon Brown October 12, 2022

Defence Therapeutics Initiates Lung Cancer Treatment Program with Its Novel AccuTOX(TM) Formulation via Intranasal

Newsfile October 12, 2022

Defence Therapeutics (CSE:DTC) is granted patents in Japan and Israel

John Ballem  September 29, 2022

Defence Therapeutics Is Granted Patents in Japan and Israel Expanding Its Novel ADC Platform Technology in the Fast Growing Antibody-Drug Conjugates Market

Newsfile September 29, 2022